TB-500
TB-500 is a seven-residue thymosin beta-4 fragment with the sequence Ac-LKKTETQ[1]. GSRS lists TB-500 with UNII QHK6Z47GTG[2]. People discuss it for tendon repair and wound healing. United States FDA meeting materials looked at TB-500 free base and acetate for wound healing[14]. Current PubMed and Europe PMC trial-paper searches found no TB-500 peptide clinical-trial paper[3]. ClinicalTrials.gov lists a public example record with no posted results[5]. A 2026 rat Achilles repair study found higher maximum load to failure with TB-500 than controls at four weeks[8].
What is TB-500?
Esposito and co-authors published the identity paper in Drug Testing and Analysis in 2012[1]. The paper identified the N-terminal acetylated 17-23 fragment of human thymosin beta-4 in a product named TB-500[1]. That makes TB-500 a fragment record, not a full-length thymosin beta-4 record.
The main reason people discuss it is tissue repair. A 2026 peer-reviewed review in Applied Sciences mapped thymosin beta-4 and TB-500 work around healing, new tissue growth, and muscle-tendon repair[6]. The United States FDA's July 2026 meeting page says TB-500 free base and TB-500 acetate were reviewed for wound healing[14].
What has been published in humans?
No published human result for exact TB-500 was found in the checked trial-paper searches. A registry plan or public example is not a published result.
| Source | Human-result finding | Funder or sponsor note | Checked |
|---|---|---|---|
| PubMed exact trial-paper search[3] | The query returned one clinical-trial paper, PMID 33318598. That paper concerns tuberculosis, not the peptide TB-500. | Not a TB-500 peptide source | 2026-08-30 |
| Europe PMC exact trial-paper search[4] | The query returned three clinical-trial hits. They concerned Terminalia bellerica, cocoa, and pulmonary tuberculosis. | Not TB-500 peptide sources | 2026-08-30 |
| NCT07487363[5] | ClinicalTrials.gov describes a public example record for TB-500 in stable heart disease. It has no posted results. | Hudson Biotech is listed as the industry sponsor. | 2026-08-30 |
| McGuire et al., Applied Sciences 2026[6] | The review screened 1,772 records and included 80 studies. One included study directly examined TB-500. That study was not a human treatment study. | The paper reports no external funding. | 2026-08-30 |
| NCT00743769[7] | This withdrawn registry record tested full-length thymosin beta-4, not TB-500. Actual enrollment was 0. | RegeneRx Biopharmaceuticals was the industry sponsor. | 2026-08-30 |
The gap is narrow. It is about exact TB-500. It does not cover every full-length thymosin beta-4 study. It does not claim that nobody has used a vial labelled TB-500. It says what the cited searches found, and where they stop.
What is TB-500 said to help with?
United States FDA meeting materials looked at TB-500 free base and TB-500 acetate for wound healing[14]. A 2026 Applied Sciences review mapped thymosin beta-4 and TB-500 work around tissue healing, new tissue growth, and muscle-tendon repair[6]. In the 2026 rat Achilles study, TB-500 had higher maximum load to failure than controls at four weeks[8].
That is the useful split. The cited sources support wound-healing and tendon-repair questions. They do not supply a published human treatment result for exact TB-500. The benefit is clear, and the limit is clear. A reader gets both in the same place. One fact does not cancel the other. The rat data helps. The human gap still matters.
What do TB-500 and BPC-157 records show together?
TB-500 and BPC-157 are separate compound records. The gym recovery hub owns the stack phrase, while this register page answers the TB-500 compound question.
The 2026 rat Achilles study compared control, BPC-157, TB-500, and combined BPC-157 plus TB-500 groups[8]. Each group contained 8 rats, and 4 tendons per group entered biomechanical testing[8]. TB-500 reached a significant maximum-load comparison against controls, and the combined group did not add benefit beyond either peptide alone[8].
No published controlled human trial of a BPC-157 and TB-500 stack was found in the cited exact trial-paper searches. Related links give context; they are not recommendations to combine compounds. The stack question belongs on the gym recovery hub, and the compound facts belong here.
What side effects and safety findings were recorded?
No human study in the checked searches supplies a side-effect rate for exact TB-500. The table keeps cell, animal, registry, and regulator findings apart.
| Source | Recorded safety finding | Funder or sponsor note | Checked |
|---|---|---|---|
| Rahaman et al., J Chromatogr B 2024[9] | Fibroblast assays found no cell toxicity for the parent peptide or tested metabolites. | PubMed lists no grants. | 2026-08-30 |
| Bicer et al., Jt Dis Relat Surg 2026[8] | No animal deaths, postoperative infections, wound complications, tendon reruptures, or protocol-related exclusions occurred during the rat study. | The authors declared no conflicts and no financial support. | 2026-08-30 |
| NCT07487363[5] | The public example record lists adverse events over 12 weeks and serious adverse events over 28 days as main outcomes. It has no posted results. | Hudson Biotech is listed as the industry sponsor. | 2026-08-30 |
| United States FDA compounding page[13] | FDA says compounded drugs with thymosin beta-4 fragment LKKTETQ may pose immune-reaction risk from aggregation and peptide-related impurities. FDA also says it has not identified human exposure data for drug products with the fragment. | United States regulator source; not a clinical trial | 2026-08-30 |
These rows do not merge into one safety score. The cell assay found no cell harm. The rat study reported no listed wound events. The FDA row is about pharmacy compounding and missing human exposure data. Each row answers a different question. Good news and missing data can both be true.
What dosage information do sources report for TB-500?
These are source reports. They are not site advice. The rows report what named sources gave, registered, or self-reported. They show where each number came from. They do not tell a reader to use that number. Source first. Number second. No site-made plan.
| Source | Reported amount | Source type | What that means here | Checked |
|---|---|---|---|---|
| Bicer et al., Jt Dis Relat Surg 2026[8] | Rats assigned to TB-500 received 60 micrograms/kg/day intraperitoneally for 30 postoperative days. | Rat study | This was a surgically repaired Achilles-tendon model in 32 rats. | 2026-08-30 |
| NCT07487363[5] | The public example says the specific dose levels are protocol-defined and not provided. | Trial-registry example | This record supplies no public administered amount. | 2026-08-30 |
| ExcelMale thread 22197[15] | One poster reported 40 mg total TB-500 and 3.3 mg every third day. | Archived forum report | This is a self-reported, self-selected account, not a study. | 2026-08-30 |
| ExcelMale thread 23060[16] | One poster reported adding TB500 at 10 mg every 5 days. | Archived forum report | This is a self-reported, self-selected account, not a study. | 2026-08-30 |
No cited approved-product source provides a TB-500 dose. No row above turns a study amount or forum amount into advice.
What do animal and laboratory studies add?
The rat result is the clearest measured benefit on this page. It is still a rat result. The animal and lab evidence stays separate from the human-evidence gap. That makes the finding useful without turning it into a human claim. It is a real result, with a real limit.
| Source | Finding | Limit | Funder and conflict note | Checked |
|---|---|---|---|---|
| Bicer et al., Jt Dis Relat Surg 2026[8] | In 32 male rats, median maximum load to failure was 37.41 N for TB-500 and 26.91 N for controls. The TB-500 versus control adjusted p value was 0.0406. | Four tendons per group entered load testing. Outcome check was at one time point after Achilles repair. | The authors declared no conflicts and no financial support. | 2026-08-30 |
| Bicer et al., Jt Dis Relat Surg 2026[8] | Total Bonar score was lower in the TB-500 group than controls, with p = 0.016. Total Movin score was lower in the TB-500 group than controls, with p = 0.017. | The paper calls the rat model exploratory. | Same paper | 2026-08-30 |
| Bicer et al., Jt Dis Relat Surg 2026[8] | Combined BPC-157 and TB-500 treatment did not confer additional benefits compared with either agent alone. | The study did not include human participants. | Same paper | 2026-08-30 |
| Rahaman et al., J Chromatogr B 2024[9] | Ac-LK was the main rat breakdown product at 0-6 hours. Ac-LKK was found up to 72 hours. | The work used human serum, enzyme systems, rat urine, and fibroblasts. | PubMed lists no grants; the paper disclosed KIST support in local notes. | 2026-08-30 |
| Rahaman et al., J Chromatogr B 2024[9] | Only Ac-LKKTE showed a significant wound-healing effect compared with control. | The abstract gives no effect size or interval. | Same paper | 2026-08-30 |
| McGuire et al., Applied Sciences 2026[6] | The peer-reviewed review found 1 direct TB-500 study among 80 included studies. That direct study was metabolite profiling and in vitro fibroblast wound-healing screening. | The review searched through 26 March 2026 and did not perform formal risk-of-bias appraisal. | The paper reports no external funding. | 2026-08-30 |
What has direct vial or product testing found?
Product tests ask whether a material matched a label or a named sequence. They do not establish a human effect. They can still help a reader judge what was in a vial or product. That is why they sit apart from the study rows. They answer the vial question, not the body question.
| Source | What was measured | What was not measured | Funder and conflict note | Checked |
|---|---|---|---|---|
| Esposito et al., Drug Test Anal 2012[1] | A product named TB-500 contained the N-terminal acetylated 17-23 fragment of thymosin beta-4, Ac-LKKTETQ. | The PubMed abstract gives no purity, sterility, endotoxin, or label-amount result. | PubMed lists no grants in the checked summary. | 2026-08-30 |
| Delcourt et al., Drug Test Anal 2023[10] | The paper analyzed products named TB500, TB1000, and SGF1000. It found TB500 and TB1000 contents were not systematically consistent with earlier descriptions. | The abstract does not give a market rate for all products labelled TB-500. | PubMed lists two Institut francais du cheval et de l'equitation grants. | 2026-08-30 |
| Mendias and Awan preprint 2026[11] | The preprint reports 4 TB-500 identity failures and labels the rate 10.0 percent. Median TB-500 purity was 97.29 percent. | The opened text does not state the TB-500 sample count. The dataset was voluntary and self-selected. | The preprint says no external funding and no conflict of interest. | 2026-08-30 |
| Mendias and Awan preprint 2026[11] | The TB-500 purity interquartile range was 93.83 to 99.59 percent. The dual-pass rate was 22.5 percent. | The preprint is not peer-reviewed. | Same preprint | 2026-08-30 |
What do user reports add?
Forum posts are self-reported and self-selected. They add lived accounts, not controlled evidence. The archived ExcelMale captures below were opened with their original URL, archive URL, capture date, and full saved thread text.
| Forum source | What the poster reported | What to remember | Checked |
|---|---|---|---|
| ExcelMale thread 22197[15] | One poster described an MRI-verified meniscus tear and wrote that he was "back to riding and squatting" after TB-500. | This is one archived forum account. No lab confirmed the product. | 2026-08-30 |
| ExcelMale thread 23060[16] | One poster reported "no discernible improvement" after oral BPC-157 and added TB500. | This is one archived forum account. It does not isolate product quality from response. | 2026-08-30 |
No count from these threads is presented as a site-wide consensus. The useful fact is that people report both positive and no-effect experiences in public discussion. The rows tell us what one person wrote. They do not say what most users felt.
What is the current evidence status, and what is the regulatory status?
Evidence status, EU status, United States FDA compounding status, and trial status are separate questions. The table keeps them separate. A search gap is not an approval status. A regulator page is not a trial result. A forum post is not a dose rule. Each answer has its own source. Each limit stays in its own row.
| Question | Current answer | Source and limit | Checked |
|---|---|---|---|
| Evidence tier | The record is tier C because direct published evidence is animal, laboratory, and product-testing evidence. | No published human result for exact TB-500 was found in the checked clinical-result searches. | 2026-08-30 |
| EU central register | The 2,731-row EMA centrally authorised medicines report generated on 22 August 2026 had no row matching TB-500, TB 500, Thymosin beta-4, or Thymosin beta 4[12]. | The EMA report covers the central route, not every national medicines route. | 2026-08-30 |
| Swedish product register | A structured scan of Läkemedelsverket's 38,369-row medicinal-product spreadsheet found none of the declared TB-500 or thymosin beta-4 terms. | A product-register absence does not classify TB-500. | 2026-08-30 |
| United States FDA compounding page | FDA lists thymosin beta-4 fragment LKKTETQ, also known as TB-500, in its compounding-risk page[13]. | This source concerns United States pharmacy compounding. It is not an approval status and not a human clinical result. | 2026-08-30 |
| United States FDA PCAC page | The July 23, 2026 meeting page says TB-500 free base and TB-500 acetate were evaluated for wound healing[14]. | FDA says advisory-committee recommendations are non-binding. | 2026-08-30 |
| Trial registry | NCT07487363 is a public example record with estimated enrollment 80 and no posted results[5]. | The record cannot be used as a published human result. | 2026-08-30 |
| Parent-peptide registry trap | NCT00743769 studied full-length thymosin beta-4 and was withdrawn with actual enrollment 0[7]. | A thymosin beta-4 registry record is not a TB-500 human result. | 2026-08-30 |
The data file is /data/register.json.
See also
- Full register - compare peptide entries.
- BPC-157 register record - read the separate BPC-157 evidence record.
- Gym recovery hub - compare recovery-related evidence across compounds.
- Vial-testing guide - see what direct tests can measure.
- COA guide - separate certificate claims from missing checks.
FAQ
What is TB500 used for?
Opened sources discuss TB-500 around wound healing and tendon repair. FDA meeting materials evaluated TB-500 free base and acetate for wound healing[14]. The strongest measured activity cited here is the 2026 rat Achilles repair study[8].
How do TB500 and BPC-157 compare?
No published human head-to-head study was found in the cited clinical-result searches. In the 2026 rat Achilles study, TB-500 reached a significant maximum-load comparison with controls, and BPC-157 did not[8]. The combination group did not add benefit beyond either peptide alone[8].
How does TB500 affect the heart?
NCT07487363 is a public example record in stable atherosclerotic cardiovascular disease[5]. It lists vascular-function and inflammation biomarkers, but it has no posted results[5]. No cited human TB-500 paper here reports a measured heart effect.
Can I take TB 500 every day?
No published human study cited here tests daily TB-500 use. The rat study administered 60 micrograms/kg/day intraperitoneally for 30 postoperative days[8]. Two forum rows report self-directed schedules, and those rows are labelled as self-reported accounts.
References
- ↑ a b c d e Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal, 2012. PMID 22962027. DOI 10.1002/dta.1402. Used for name, sequence, first-seen month, and product test; checked 2026-08-30.
- ↑ a b c NCATS GSRS. TB-500 substance search, UNII QHK6Z47GTG. GSRS QHK6Z47GTG. Used for UNII and residue string; checked 2026-08-30.
- ↑ a b c National Library of Medicine. Exact PubMed TB-500 trial-paper search. Used for current PubMed trial-paper absence and PMID 33318598 tuberculosis false hit; checked 2026-08-30.
- ↑ Europe PMC. Exact Europe PMC TB-500 trial-paper search. Used for current Europe PMC trial-paper absence and three non-peptide hits; checked 2026-08-30.
- ↑ a b c d e f g h Hudson Biotech. TB-500 heart biomarker public example record. Trial registry, 2026. NCT07487363. Used for public example wording, sponsor, planned count, outcomes, no public dose, and no posted results; checked 2026-08-30.
- ↑ a b c d McGuire FP, Hughes E, Maak T, Cushman DM. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair. Applied Sciences, 2026. DOI 10.3390/app16126202. Used for the 1,772-record screen, 80 included studies, one direct TB-500 study, limits, and no external funding; checked 2026-08-30.
- ↑ a b RegeneRx Biopharmaceuticals. Thymosin beta-4 intravenous safety study. Trial registry, 2008. NCT00743769. Used for parent-peptide status, withdrawal, sponsor, actual enrollment 0, and no posted results; checked 2026-08-30.
- ↑ a b c d e f g h i j k l m n Bicer O, Adanir O, Guleryuz Y, Balci EC, Dincel YM, Yenigun MY, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Jt Dis Relat Surg, 2026. PMID 42542926. DOI 10.52312/jdrs.2026.2951. Used for rat dose, four-group plan, tendon results, no animal-complication row, limits, conflicts, and funding; checked 2026-08-30.
- ↑ a b c Rahaman KA, Muresan AR, Min H, Son J, Han H-S, Kang M-J, Kwon O-S. Simultaneous quantification of TB-500 and its metabolites. J Chromatogr B, 2024. PMID 38382158. DOI 10.1016/j.jchromb.2024.124033. Used for metabolism, cell assay, Ac-LK, Ac-LKK, Ac-LKKTE, and cell-toxicity findings; checked 2026-08-30.
- ↑ Delcourt V et al. TB500/TB1000 and SGF1000. Drug Test Anal, 2023. PMID 36482504. DOI 10.1002/dta.3421. Used for product-testing result and grant notes; checked 2026-09-05.
- ↑ a b Mendias CL, Awan TM. Research-grade peptide tests. Preprints.org, 2026. DOI 10.20944/preprints202604.1748.v1. Used for TB-500 identity failures, purity, dual-pass rate, self-selected sample limits, and funding statement; checked 2026-08-30.
- ↑ a b European Medicines Agency. Medicines output report. Generated 22 August 2026. Used for the central EMA-register absence and central-route limit; checked 2026-08-30.
- ↑ a b c United States FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current 22 April 2026. Used for TB-500 identity, compounding-risk wording, and human-exposure-data absence; checked 2026-08-30.
- ↑ a b c d e United States FDA. July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. Used for TB-500 free base and acetate wound-healing agenda item and non-binding advisory-committee status; checked 2026-08-30.
- ↑ a b ExcelMale. BPC-157 and/or TB-500 Results?, thread 22197. Wayback capture 7 November 2025. Used for self-reported meniscus and TB-500 dose account; checked 2026-08-30.
- ↑ a b ExcelMale. BPC 157 TB500, thread 23060. Wayback capture 17 November 2025. Used for self-reported no-effect and TB-500 dose account; checked 2026-08-30.